A novel homozygous TPM1 mutation in familial pediatric hypertrophic cardiomyopathy and in silico screening of potential targeting drugs.
Author | Carlus, S J |
Author | Almuzaini, I S |
Author | Karthikeyan, M |
Author | Loganathan, L |
Author | Al-Harbi, G S |
Author | Carlus, F H |
Author | Al-Mazroea, A H |
Author | Morsy, M M |
Author | Abo-Haded, H M |
Author | Abdallah, A M |
Author | Al-Harbi, K M |
Available date | 2020-08-09T07:50:39Z |
Publication Date | 2020-07-01 |
Publication Name | European Review for Medical and Pharmacological Sciences |
Identifier | http://dx.doi.org/10.26355/eurrev_202007_22299 |
Citation | Carlus SJ, Almuzaini IS, Karthikeyan M, et al. A novel homozygous TPM1 mutation in familial pediatric hypertrophic cardiomyopathy and in silico screening of potential targeting drugs. Eur Rev Med Pharmacol Sci. 2020;24(14):7732-7744. doi:10.26355/eurrev_202007_22299 |
ISSN | 1128-3602 |
Abstract | Familial hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease. While sarcomeric gene mutations explain many HCM cases, the genetic basis of about half of HCM cases remains elusive. Here we aimed to identify the gene causing HCM in a non-consanguineous Saudi Arabian family with affected family members and a history of sudden death. The impact of the identified mutation on protein structure and potential drug targets were evaluated in silico. Triplets (two HCM subjects and one patent ductus arteriosus (PDA) case) and unaffected parents were screened by targeted next-generation sequencing (NGS) for 181 candidate cardiomyopathy genes. In silico structural and functional analyses, including protein modeling, structure prediction, drug screening, drug binding, and dynamic simulations were performed to explore the potential pathogenicity of the variant and to identify candidate drugs. A homozygous missense mutation in exon 1 of TMP1 (assembly GRCh37-chr15: 63340781; G>A) was identified in the triplets [two HCM and one patent ductus arteriosus (PDA)] that substituted glycine for arginine at codon 3 (p.Gly3Arg). The parents were heterozygous for the variant. The mutation was predicted to cause a significant and deleterious change in the TPM1 protein structure that slightly affected drug binding, stability, and conformation. In addition, we identified several putative TPM1-targeting drugs through structure-based in silico screening. TPM1 mutations are a common cause of HCM and other congenital heart defects. To date, TPM1 has not been associated with isolated PDA; to our knowledge, this is the first report of the homozygous missense variation p.Gly3Arg in TPM1 associated with familial autosomal recessive pediatric HCM and PDA. The identified candidate TPM1 inhibitors warrant further prospective investigation. |
Sponsor | This research was supported by the Strategic Technologies Programs of the National Plan for Science, Technology and Innovation (MAARIFAH), Kingdom of Saudi Arabia. Project No: 12-MED3174-05, through the Science and Technology Unit (STU), Taibah University, Al Madinah Al Munawwarah, Kingdom of Saudi Arabia. |
Language | en |
Publisher | Verduci Editore s.r.l. |
Subject | Cardiomyopathy TMP1 mutations in silico |
Type | Article |
Pagination | 7732-7744 |
Issue Number | 14 |
Volume Number | 24 |
ESSN | 2284-0729 |
Files in this item
This item appears in the following Collection(s)
-
Biomedical Sciences [711 items ]